Israeli Biotech company says it can revolutionize drug development
Tissue Dynamics Ltd., an Israeli biotechnology company, says it can cut drug development cost by 40% to 80% and the time required by 30% to 50%.
Stay updated with breaking news from Tissue Dynamics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tissue Dynamics Ltd., an Israeli biotechnology company, says it can cut drug development cost by 40% to 80% and the time required by 30% to 50%.
Integrated Tissue Dynamics is looking for funding to further a study that addresses...
Five Israeli teams fighting for a COVID-19 cure Posted on Israeli scientists and researchers are racing to find a cure for COVID-19, as global consensus is forming among medical professionals that vaccination is not going to eliminate corona. When Israel launched its mass vaccination campaign, there were many who believed there would no longer be a need for medication, Prof. Eli Schwartz, founder of the Center for Travel Medicine and Tropical Disease at Sheba Medical Center in Tel Hashomer, told The Jerusalem Post. “Now we know that this was an illusion,” he said. “Even in Israel, no...
Early clinical data demonstrates the efficacy of existing drug in treating COVID-19 In what has the potential to significantly change how Corona patients are being treated and the severity of the disease, research spearheaded at Jerusalem's Hebrew University gathered early clinical evidence demonstrating the efficacy of an existing drug in treating COVID-19. The study was presented at the recent SPARK Conference on Generic Drug Repurposing for COVID-19 by Professor Yaakov Nahmias, Director of the Center for Bioengineering at Hebrew University. Nahmias applied a well-established existing drug ...
Credit: Daniel Hanoch In what has the potential to significantly change how Corona patients are being treated and the severity of the disease, research spearheaded at Jerusalem's Hebrew University gathered early clinical evidence demonstrating the efficacy of an existing drug in treating COVID-19. The study was presented at the recent SPARK Conference on Generic Drug Repurposing for COVID-19 by Professor Yaakov Nahmias, Director of the Center for Bioengineering at Hebrew University. Nahmias applied a well-established existing drug to address the buildup of fats in human lung cells caused by...